Professor of Urology, Professor of Oncology, Professor of Pathology, Johns Hopkins University School of Medicine; David Hall McConnell Professor and Director of Urology, Urologist -in-Chief, Department of Urology, Oncology
Urology
Dr. Alan W. Partin, MD
|
|
Give Review
Dr. Alan W. Partin is an expert in the field of Urology. He studied medicine at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a one of the best medicals schools. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care He received 7 awards: "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer", "Top Doctors:Baltimore Area", "Top Doctors:Washington-Baltimore", "Super Doctor" and "Top MD". Alan Partin is a published MD as well. He has 99 publications published. The latest was: Urinary Biomarkers for Prostate Cancer. Alan Partin is registered with Medicare.
Publications
- Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men.
- Urinary Biomarkers for Prostate Cancer.
- Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
- Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate Cancer.
- Importance of Reporting The Gleason Score at the Positive Surgical Margin Site: An Analysis of 4,082 Consecutive Radical Prostatectomy Cases.
- Outcomes of men with an Elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
- Is clinical stage T2c prostate Cancer an intermediate- or high-risk disease?
- The Prostate Health Index (phi) Selectively Identifies Clinically-Significant Prostate Cancer.
- Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
- Obesity and Long-Term Survival after Radical Prostatectomy.
- A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate Cancer.
- Robotic Prostatectomy Diffusion Safety Concerns: Reality or Just Illusion?
- Know your nomograms.
- The Relationship Between the Extent of Extraprostatic Extension and Survival Following Radical Prostatectomy.
- Indications for Intervention During Active Surveillance of Prostate Cancer: A Comparison of the Johns Hopkins and PRIAS Protocols.
- High prevalence of screen-detected prostate Cancer in West Africans: implications for racial disparity of prostate Cancer.
- Clinical Validation of an Epigenetic Assay to Predict Negative Histopathological Results in Repeat Prostate Biopsies.
- Allogeneic versus autologous Blood transfusion and survival after radical prostatectomy.
- Identification of men with the highest risk of early disease recurrence after radical Prostatectomy.
- Adenocarcinoma of the Prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical Prostatectomy and prognosis.
- Very-high-risk localized prostate Cancer: definition and outcomes.
- Re: Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study: I. Y. Kim, P. K. Modi, E. Sadimin, Y.-S. ...
- A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate Cancer before radical prostatectomy.
- Modeling grade progression in an active surveillance study.
- Pathological and oncologic outcomes for men with positive lymph nodes at radical Prostatectomy: The Johns Hopkins Hospital 30-year experience.
- African American men with very low-risk prostate Cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option f...
- Comparison of biochemical recurrence-free survival between periprostatic and pelvic lymph node metastases of prostate Cancer.
- Trends in immediate perioperative morbidity and delay in discharge after open and minimally invasive radical Prostatectomy (RP): a 20-year institutional experience.
- 2013 AUA Guideline on Early Detection of Prostate Cancer Continues to Support Rational, Limited Screening.
- Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration.
- Pathological Outcomes in Men with Low Risk and Very Low Risk Prostate Cancer: Implications on the Practice of Active Surveillance.
- Prognostic Gleason grade grouping: data based on the modified Gleason scoring system.
- Multiparametric magnetic resonance imaging findings in men with low-risk prostate Cancer followed using active surveillance.
- Increased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance.
- Multiple cores of Gleason score 6 correlate with favourable findings at radical Prostatectomy.
- Contemporaneous comparison of open vs minimally-invasive radical prostatectomy for high-risk prostate Cancer.
- An updated prostate Cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.
- The impact of prostate volume, number of biopsy cores, and AUA symptom score on the sensitivity of Cancer detection using the Prostate Cancer Prevention Trial Risk Cal...
- Geometric evaluation of systematic transrectal ultrasound guided Prostate biopsy.
- Association of -2proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer.
- Impact of Robotic Technique and Surgical Volume on the Cost of Radical Prostatectomy.
- Causes of Death After Radical Prostatectomy at a Large Tertiary Center.
- Radical prostatectomy outcome in men 65 years old or older with low risk prostate Cancer.
- Germline mutations in HOXB13 and prostate-Cancer risk.
- High-Grade Prostatic Adenocarcinoma Present in a Single Biopsy Core as Associated With Increased Extraprostatic Extension, Seminal Vesicle Invasion, and Positive Surgi...
- Fifth-generation digital immunoassay for Prostate-specific antigen by single molecule array technology.
- AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical Prostatectomy.
- Updating risk prediction tools: A case study in prostate Cancer.
- Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial Prostate biopsies.
- Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate Cancer aggressiveness.
- PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients.
- Clinical evaluation of a novel method for the measurement of Prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival aft...
- A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate Cancer.
- Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate Cancer.
- The natural history of metastatic progression in men with Prostate-specific antigen recurrence after radical Prostatectomy: long-term follow-up.
- Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.
- Obesity and prostate enlargement in men with localized prostate Cancer.
- Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate Cancer active surveillance participa...
- Preoperative characteristics of men with unfavorable high-Gleason prostate Cancer at radical prostatectomy.
- Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia.
- A contemporary analysis of outcomes of adenocarcinoma of the Prostate with seminal vesicle invasion (pT3b) after radical Prostatectomy.
- Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous Prostate-specific antigen measurement, clinical stage and...
- A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in th...
- Treatment decision-making for localized prostate Cancer: What younger men choose and why.
- Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience.
- Repeat prostate biopsies predict location of index Cancer in an active surveillance cohort.
- ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate Cancer treatment among men enrolled in an active surveillanc...
- Predicting 15-year prostate Cancer specific mortality after radical prostatectomy.
- Best of the AUA Annual Meeting: Highlights From the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.
- Imaging utilization for the staging of clinically localized prostate Cancer.
- Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical Prostatectomy: an analysis using pro...
- Tumor grade at margins of resection in radical Prostatectomy specimens is an independent predictor of prognosis.
- Long Term-Survival after Radical Prostatectomy for men with High Gleason Sum.
- Nuclear roundness variance predicts prostate Cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow-up after radical prostat...
- Prediction of mortality after radical Prostatectomy by Charlson comorbidity index.
- Long-term survival after radical Prostatectomy for men with high Gleason sum in pathologic specimen.
- Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate Cancer surveillance program.
- A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate Cancer.
- A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate Cancer detection and correlating with ca...
- Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.
- Complications of pelvic lymphadenectomy: do the risks outweigh the benefits?
- The significance of a positive Bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted.
- Validation of the partin nomogram for prostate Cancer in a national sample.
- PCA3 Urinary Biomarker for Prostate Cancer.
- What is the true mortality benefit of Prostate-specific antigen screening?
- Open versus minimally invasive radical Prostatectomy.
- Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate Cancer.
- Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate Cancer: evaluation of drug-specific biomarkers.
- Small integrin-binding proteins as serum markers for prostate Cancer detection.
- Individual and cumulative effect of prostate Cancer risk-associated variants on clinicopathologic variables in 5,895 prostate Cancer patients.
- Analysis of a serum test for prostate Cancer that detects a second epitope of EPCA-2.
- Body mass index and Prostate specific antigen as predictors of adverse pathology and biochemical recurrence after Prostatectomy.
- DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate Cancer prediction.
- Predicting prostate Cancer biochemical recurrence using a panel of serum proteomic biomarkers.
- Endoglin (CD105) as a urinary and serum marker of prostate Cancer.
- Robotic image-guided needle interventions of the Prostate.
- Randomized trials of prostate Cancer screening.
- Biomarkers for prostate Cancer.
Schools
Johns Hopkins University School Of Medicine
John Hopkins Hospital
Johns Hopkins Hospital
University Of Ms
Procedures Preformed
- Biopsy
- Prostate Removal
- Prostate Removal (incl. TURP)
- Prostatectomy With Robotic Assistance
Conditions Treated
- Bladder Cancer
- Blood in Urine (Hematuria)
- Elevated PSA (Prostate Specific Antigen)
- Erectile Dysfunction
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
- Super Doctor
- Top MD
Education
-
Johns Hopkins University -
Johns Hopkins University School of Medicine
Hospital
-
Johns Hopkins Hospital -
Johns Hopkins Bayview Medical Center -
Sibley Memorial Hospital
Drug Facts
| NPI NUMBER | 1437106267 | |
| NPPES Provider LastName | PARTIN | |
| NPPES Provider FirstName | ALAN | |
| NPPES Provider ZIPCode | 212870006 | |
| NPPES Provider State | MD | |
| Specialty Description | Urology | |
| Total Claim Count | 82.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1437106267 |
| Last Name Of The Provider | PARTIN |
| First Name Of The Provider | ALAN |
| View All |
Similar Doctors
|
Dr. Arthur L. Burnett, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mohamad E. Allaf, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Harold J. Alfert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anand M. Dhanda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward M. Schaeffer, MD |
|
|
Dr. Terren M. Himelfarb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ray Stutzman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Pravin K. Rao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth F. Langer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christen A. Alevizatos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Heather N. Di Carlo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christian Pavlovich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Garjae D. Lavien, MD |
|
|
Dr. Jeffrey J. Tosoian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nikhil Waingankar, MD |
|
|
Dr. Nikolai Sopko, MD |